Journal
EMERGING INFECTIOUS DISEASES
Volume 24, Issue 1, Pages 40-48Publisher
CENTERS DISEASE CONTROL
DOI: 10.3201/eid2401.170864
Keywords
-
Categories
Funding
- World Health Organization
- Instituto de Salud Carlos III (Fondo Europeo de Desarrollo Regional) [PI13/01478, CES10/021-I3SNS]
- Departament d'Universitats i Recerca de la Generalitat de Catalunya, Agencia de Gestio d'Ajuts Universitaris i de Recerca [2014SGR263]
- Science and Engineering Research Board, Department of Science & Technology, Government of India [SB/OS/PDF-043/2015-16]
- Spanish Agency for International Cooperation
Ask authors/readers for more resources
One of the fundamental steps toward malaria control is the use of antimalarial drugs. The success of antimalarial treatment can be affected by the presence of drug-resistant populations of Plasmodium falciparum. To assess resistance, we used molecular methods to examine 351 P. falciparum isolates collected from 4 sentinel sites in Mozambique for K13, pfmdr1, pfcrt, and pfdhps polymorphisms and for plasmepsin2 (pfpm2) and pfmdr1 copy numbers. We found multiple copies of pfpm2 in 1.1% of isolates. All isolates carried K13 wild-type alleles (3D7-like), except 4 novel polymorphisms (Leu619Leu, Phe656Ile, Val666Val, Gly690Gly). Prevalence of isolates with pfcrt mutant (K76T) allele was low (2.3%). Prevalence of isolates with pfdhps mutant alleles (A437G and K540E) was > 80%, indicating persistence of sulfadoxine/pyrimethamine resistance; however, markers of artemisinin were absent, and markers of piperaquine resistance were low. Piperaquine resistance isolates may spread in Mozambique as dihydroartemisinin/piperaquine drug pressure increases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available